Research in the Griffin Lab
Our lab seeks to identify new and better immunotherapies for patients with cancer and immunologic disease.
To achieve this goal, we use a collaborative and interdisciplinary research model that draws from cancer epigenetics, tumor immunology, genome editing, and computational biology, among other fields.
We seek a systematic understanding of:
1. How cancer cells adapt to and avoid detection by the immune system
2. How genome variation impacts immune regulation in cancer cells
3. Proteins that can be targeted therapeutically to restore, amplify, or engage anti-tumor immunity
We are particularly interested in defining how the epigenome adapts to selective pressures applied by the immune system. Prior work from our group and others has identified epigenetic silencing of repetitive elements, including endogenous retroviruses, as a touchpoint for multiple immunoregulatory pathways in cancer and immune-mediated diseases. We seek to exploit these pathways therapeutically to enhance the efficacy and scope of immunotherapies for patients.
To learn more about our science please see our recent publications or contact us directly.
Our lab seeks to identify new and better immunotherapies for patients with cancer and immunologic disease.
To achieve this goal, we use a collaborative and interdisciplinary research model that draws from cancer epigenetics, tumor immunology, genome editing, and computational biology, among other fields.
We seek a systematic understanding of:
1. How cancer cells adapt to and avoid detection by the immune system
2. How genome variation impacts immune regulation in cancer cells
3. Proteins that can be targeted therapeutically to restore, amplify, or engage anti-tumor immunity
We are particularly interested in defining how the epigenome adapts to selective pressures applied by the immune system. Prior work from our group and others has identified epigenetic silencing of repetitive elements, including endogenous retroviruses, as a touchpoint for multiple immunoregulatory pathways in cancer and immune-mediated diseases. We seek to exploit these pathways therapeutically to enhance the efficacy and scope of immunotherapies for patients.
To learn more about our science please see our recent publications or contact us directly.